Rabacfosadine NEW
| Price | $158 | $389 | $579 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-20 |
Product Details
| Product Name: Rabacfosadine | CAS No.: 859209-74-8 |
| Purity: 99.43% | Supply Ability: 10g |
| Release date: 2024/11/20 |
Product Introduction
Bioactivity
| Name | Rabacfosadine |
| Description | Rabacfosadine (GS-9219) is a novel dual pre-drug of the acyclic nucleotide phosphonate PMEG to tumor lymphocytes for the study of lymphoma. |
| In vitro | Rebaarsen inhibits the proliferation of mitogen-stimulated T and B lymphocytes as determined by BrdUrd binding assay (EC50 135 and 42 nM, respectively). GS-9219 showed strong antiproliferative activity against activated lymphocytes and hematopoietic tumor cell lines. Labafaxadine is converted to its active metabolite, PMEG diphosphate, by enzymatic hydrolysis, deamination and phosphorylation in lymphocytes. In this paper, we investigated the ability of rabafaxadine to inhibit the proliferation of activated lymphocytes and hematopoietic tumor cells. To compare the activity of GS-9219 in dividing and non-dividing cells, the activity of Rabacfosadine in these cell populations was assessed using the metabolism-based XTT sodium assay rather than the BrdUrd assay.The results of the XTT assay showed that the EC50 values of Rabacfosadine differed from those in quiescent (EC50=17.2 μM) and proliferating cells (EC50=135 nM). ) in quiescent cells (EC50=17.2 μM) and proliferating cells (EC50=135 nM) with a 127-fold difference in EC50 values. These results suggest that Rabatadine has a great selectivity for actively replicating lymphoblastoid cells [1]. |
| In vivo | Rabatadine has potent single-agent activity in dogs with lymphoma by a mechanism of action different from that of doxorubicin. Dogs are treated alternately with rabafenacin (1.0 mg/kg, i.v., weeks 0, 6, and 12) and doxorubicin (30 mg/m2, i.v., weeks 3, 9, and 15). Dogs that achieved a complete response (CR) were evaluated at monthly follow-up visits. Complete clinicopathologic evaluations were performed every 21 days and remission and adverse events (AEs) were assessed. Acute AEs (occurring within 21 days of the first dose of each drug) were compared between labradine and doxorubicin in 46 dogs with at least 1 dose of each drug [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 80 mg/mL (151.94 mM), Sonication is recommended. |
| Keywords | VDC 1101 | GS9219 | Rabacfosadine | GS 9219 | VDC1101 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Capecitabine | Gemcitabine hydrochloride | 5-Azacytidine | Doxifluridine | 5-BrdU | Adenosine 5'-monophosphate disodium salt | Orotic acid | Ganciclovir |
| Related Compound Libraries | Bioactive Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/1kg |
Hpets Biotech Company (Chongqing) Co.,ltd
|
2023-03-21 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY